Literature DB >> 32934060

Adrenal insufficiency and checkpoint inhibitors for cancer.

Daniel L Morganstein1, James Larkin2.   

Abstract

Entities:  

Year:  2020        PMID： 32934060      PMCID： PMC7539714          DOI： 10.7861/clinmed.Let.20.5.8

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  5 in total

1.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

2.  Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma.

Authors:  Kapil Agarwal; Nadia Yousaf; Daniel Morganstein
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

Review 3.  Immunotherapy-induced endocrinopathies: assessment, management and monitoring.

Authors:  Edson Nogueira; Tom Newsom-Davis; Daniel L Morganstein
Journal:  Ther Adv Endocrinol Metab       Date:  2019-12-25       Impact factor: 3.565

4.  Guidance for the prevention and emergency management of adult patients with adrenal insufficiency.

Authors:  Helen Simpson; Jeremy Tomlinson; John Wass; John Dean; Wiebke Arlt
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

5.  SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.

Authors:  C E Higham; A Olsson-Brown; P Carroll; T Cooksley; J Larkin; P Lorigan; D Morganstein; P J Trainer
Journal:  Endocr Connect       Date:  2018-07       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.